SypeStype
11-10-2022, 06:06 PM
tamoxifen usage ([Only registered and activated users can see links]) Analysing tumours from a patient with EGFRi resistant NSCLC, the authors discovered that the patient had polyclonal resistance driven by amplification of the original EGFR mutation, acquisition of a gatekeeper mutation on EGFR, acquisition of BRAF V600E mutation, and MET amplification